Vericel (VCEL) Share-based Compensation (2010 - 2026)
Vericel (VCEL) posted Share-based Compensation of $9.1 million for Q2 2026, down 19.58% sequentially from $11.3 million in Q1 2026, and down 10.42% YoY from $10.1 million in Q2 2025.
Vericel (VCEL) Share-based Compensation (2010 - 2026) Analysis & Trends
Vericel has reported Share-based Compensation for 17 years, with the latest figure at $9.1 million in Q2 2026.
- Quarterly Share-based Compensation fell 10.42% year-over-year to $9.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $37.5 million (down 3.32% YoY) and the FY2025 annual result came in at $38.8 million, up 6.23% from the prior year.
- Share-based Compensation retreated to $9.1 million in Q2 2026 per VCEL's latest filing, from $11.3 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $12.5 million in Q4 2023 and troughed at $7.7 million in Q4 2022.
- A 5-year average of $9.5 million and a median of $9.2 million in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation jumped 62.07% in 2023, then tumbled 36.89% in 2024.
- Over 5 years, Share-based Compensation stood at $7.7 million in 2022, then surged by 62.07% to $12.5 million in 2023, then plunged by 36.89% to $7.9 million in 2024, then increased by 6.39% to $8.4 million in 2025, then increased by 7.84% to $9.1 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $9.1 million, $11.3 million, and $8.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | 9.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.08 Mn |
| Jun 30, 2026 | 9.08 Mn |
| Mar 31, 2026 | 11.29 Mn |
| Mar 31, 2026 | 11.29 Mn |
| Dec 31, 2025 | -6.65 Mn |
| Dec 31, 2025 | -6.65 Mn |
| Sep 30, 2025 | -15.00 Mn |
| Sep 30, 2025 | -15.00 Mn |
| Jun 30, 2025 | 10.14 Mn |
| Jun 30, 2025 | 10.14 Mn |
| Mar 31, 2025 | 11.51 Mn |
| Mar 31, 2025 | 11.51 Mn |
| Dec 31, 2024 | -25.29 Mn |
| Dec 31, 2024 | -25.29 Mn |
| Sep 30, 2024 | 25.54 Mn |
| Sep 30, 2024 | 25.54 Mn |
| Jun 30, 2024 | -1.86 Mn |
| Jun 30, 2024 | -1.86 Mn |
| Mar 31, 2024 | 4.90 Mn |
| Mar 31, 2024 | 4.90 Mn |